medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-19-18-21medalphabet-2771Research ArticleСтатьиМиелопероксидаза, тропонин I и С-реактивный протеин в крови у пациентов до и после аортокоронарного шунтированияMyeloperoxidase, troponin I and C-reactive protein in blood of patients before and after coronary artery bypass graftinghttps://orcid.org/0000-0003-1221-2396ШешуринаТ. А.SheshurinaT. A.

Татьяна Андреевна Шешурина, ст. преподаватель, врач клинической лабораторной диагностики

кафедра биохимии

Санкт-Петербург

Tatiana A. Sheshurina, lecturer, doctor of clinical laboratory diagnostics

Dept of Biochemistry

Saint Petersburg

ФГБОУ ВО «Национальный государственный университет физической культуры спорта и здоровья имени П. Ф. Лесгафта»; ГБУЗ «Городской врачебно-физкультурный диспансер»РоссияNational State University of Physical Culture, Sports and Health n. a. P. F. Lesgaft; City Medical and Physical Education DispensaryRussian Federation202214102022019Современная лаборатория (2)1821Copyright © Шешурина Т.А., 20222022Шешурина Т.А.Sheshurina T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2771

   Изучение динамики лабораторных маркеров до и после проведения операций на сердце позволяет прогнозировать риски развития послеоперационных осложнений. Тропонин I является «золотым стандартом» диагностики острого инфаркта миокарда, но при повышении маркера после операции на сердце трактовка результатов может представлять сложности. Поэтому поиск новых комбинаций лабораторных маркеров может помочь в оценке степени повреждения миокарда после оперативного вмешательства, а также рисков развития осложнений. Миелопероксидаза, как новый лабораторный показатель, представляет интерес, так как существует много исследований о прогностическом значении повышения этого маркера у пациентов с ишемической болезнью сердца в развитии сердечно-сосудистых осложнений. В настоящем исследовании произведена оценка динамики миелопероксидазы, тропонина I и С-реактивного протеина у пациентов с подтвержденным диагнозом «ишемическая болезнь сердца» до и после плановой операции аортокоронарного шунтирования в условиях искусственного кровообращения. Получены следующие результаты: повышенный уровень миелопероксидазы плазмы крови у пациентов до операции является дополнительным показателем в оценке риска послеоперационных осложнений независимо от концентрации С-реактивного протеина. Выявлена корреляционная связь между концентрацией тропонина I и уровнем миелопероксидазы в крови, а также между длительностью искусственного кровообращения и уровнем МПО через 24 часа после оперативного вмешательства.

   The study of dynamics of laboratory markers before and after heart surgery makes it possible to predict the risks of postoperative complications. Troponin I is ‘the gold standard’ for diagnosing acute myocardial infarction, but with an increase in the marker after heart surgery, the interpretation of the results can be difficult. Therefore, the search for new combinations of laboratory markers can help in assessing the degree of myocardial damage after surgery, as well as the risk of complications. Myeloperoxidase as a new laboratory indicator is of interest, since there are many studies on the prognostic value of an increase in this marker in patients with coronary heart disease in the development of cardiovascular complications. In the present study, the dynamics of myeloperoxidase, troponin I, and C-reactive protein in patients (n = 60) with a confirmed diagnosis of coronary heart disease before and after elective coronary artery bypass grafting under cardiopulmonary bypass was assessed. The following results were obtained: an increased level of myeloperoxidase in blood plasma in patients before surgery is an additional indicator in assessing the risk of postoperative complications, regardless of the concentration of C-reactive protein. A correlation was found between the concentration of troponin I and the level of myeloperoxidase in the blood, as well as between the duration of cardiopulmonary bypass and the level of MPO 24 hours after surgery.

тропонин IмиелопероксидазаС-реактивный протеинишемическая болезнь сердцааортокоронарное шунтированиеtroponin ImyeloperoxidaseC-reactive proteincoronary heart diseasecoronary artery bypass graftingReferencesYousuf O. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? O. Yousuf, B. D. Mohanty, S. S. Martin [et al.]. J Am Coll Cardiol. 2013. Vol. 62, No. 5. P. 397–408.Yousuf O. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? O. Yousuf, B. D. Mohanty, S. S. Martin [et al.]. J Am Coll Cardiol. 2013. Vol. 62, No. 5. P. 397–408.Singh U. C-Reactive Protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: Implications for acute coronary syndromes U. Singh, S. Devaraj, I. Jialal Clin Chem. 2009. Vol. 55, No. 2. P. 36–364Singh U. C-Reactive Protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: Implications for acute coronary syndromes U. Singh, S. Devaraj, I. Jialal Clin Chem. 2009. Vol. 55, No. 2. P. 36–364Nussbaum C. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease C. Nussbaum, A. Klinke, M. Adam [et al.]. Antioxid Redox Signal. 2013. Vol. 18, No. 6. P. 692–713.Nussbaum C. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease C. Nussbaum, A. Klinke, M. Adam [et al.]. Antioxid Redox Signal. 2013. Vol. 18, No. 6. P. 692–713.Teng N. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture, N. Teng, G. J. Maghzal, J. Talib, I. Rashid [et al.]. Redox Rep. 2017. Vol. 22, No. 2. P. 51–73.Teng N. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture, N. Teng, G. J. Maghzal, J. Talib, I. Rashid [et al.]. Redox Rep. 2017. Vol. 22, No. 2. P. 51–73.Patel A. A. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation A. A. Patel, Y. Zhang, J. N. Fullerton, L. Boelen [et al.]. J Exp Med. 2017. Vol. 214. P. 1913–1923.Patel A. A. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation A. A. Patel, Y. Zhang, J. N. Fullerton, L. Boelen [et al.]. J Exp Med. 2017. Vol. 214. P. 1913–1923.Koeth R. A. Chapter one – myeloperoxidase in cardiovascular disease R. A. Koeth, V. Haselden, W. H. Tang Adv Clin Chem. 2013. Vol. 62. P. 1–32.Koeth R. A. Chapter one – myeloperoxidase in cardiovascular disease R. A. Koeth, V. Haselden, W. H. Tang Adv Clin Chem. 2013. Vol. 62. P. 1–32.Narula J. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques J. Narula, M. Nakano, R. Virmani [et al.]. J Am Coll Cardiol. 2013. Vol. 61, No. 10. P. 1041–1051.Narula J. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques J. Narula, M. Nakano, R. Virmani [et al.]. J Am Coll Cardiol. 2013. Vol. 61, No. 10. P. 1041–1051.Baseri M. Myeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina M. Baseri, R. Heidari, B. Mahaki [et al.]. Adv Biomed Res. 2014. Vol. 3. P. 137.Baseri M. Myeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina M. Baseri, R. Heidari, B. Mahaki [et al.]. Adv Biomed Res. 2014. Vol. 3. P. 137.Rebeiz A. G. Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. A. G. Rebeiz, H. M. Tamim, R. M. Sleiman [et al.]. Coron Artery Dis. 2011. Vol. 22, No. 8. P. 553–558.Rebeiz A. G. Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. A. G. Rebeiz, H. M. Tamim, R. M. Sleiman [et al.]. Coron Artery Dis. 2011. Vol. 22, No. 8. P. 553–558.Oyenuga, A. O. Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study A. O. Oyenuga, D. Couper, K. Matsushita K. [et al.]. PLoS ONE. 2018. Vol. 13, No. 10. P. 1–9.Oyenuga, A. O. Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study A. O. Oyenuga, D. Couper, K. Matsushita K. [et al.]. PLoS ONE. 2018. Vol. 13, No. 10. P. 1–9.Rashid I. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque I. Rashid, G. J. Maghzal [et al.]. European Heart Journal. 2018. Vol. 39, No. 35. P. 3301–3310.Rashid I. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque I. Rashid, G. J. Maghzal [et al.]. European Heart Journal. 2018. Vol. 39, No. 35. P. 3301–3310.Samsamshariat S. Z. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease S. Z. Samsamshariat, G. Basati, A. Movahedian [et al.]. Biomark Med. 2011. Vol. 5. P. 377–385.Samsamshariat S. Z. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease S. Z. Samsamshariat, G. Basati, A. Movahedian [et al.]. Biomark Med. 2011. Vol. 5. P. 377–385.Alam S. R. Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial. S. R. Alam, S. C. Lewis, V. Zamvar. Heart. 2015. Vol. 101, No. 20. P. 1639–1645.Alam S. R. Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial. S. R. Alam, S. C. Lewis, V. Zamvar. Heart. 2015. Vol. 101, No. 20. P. 1639–1645.Stankovic S. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention S. Stankovic, M. Asanin, N. Majkic-Singh [et al.]. Clin Lab. 2012. Vol. 58, No. 1–2. P. 125–131.Stankovic S. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention S. Stankovic, M. Asanin, N. Majkic-Singh [et al.]. Clin Lab. 2012. Vol. 58, No. 1–2. P. 125–131.Chang P. Y. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation P. Y. Chang, T. L. Wu, C. C. Hung, K. C. Tsao [et al.]. Clin Chim Acta. 2006. Vol. 373, No. 1–2. P. 158–163.Chang P. Y. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation P. Y. Chang, T. L. Wu, C. C. Hung, K. C. Tsao [et al.]. Clin Chim Acta. 2006. Vol. 373, No. 1–2. P. 158–163.Ruparelia N. Inflammatory processes in cardiovascular disease: a route to targeted therapies N. Ruparelia, J. T. Chai, E. A. Fisher, R. P. Choudhury Nat Rev Cardiol. 2017. Vol. 14, No. 3. P. 133–144.Ruparelia N. Inflammatory processes in cardiovascular disease: a route to targeted therapies N. Ruparelia, J. T. Chai, E. A. Fisher, R. P. Choudhury Nat Rev Cardiol. 2017. Vol. 14, No. 3. P. 133–144.

The authors declare that there are no conflicts of interest present.